DeepMed Research

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Phase 2

Completed

Conditions: Liposarcoma,Myxoid

Interventions: Drug: Trabectedin
Drug: Dexamethasone

First Posted Date: 2007-12-24

Last Posted Date: 2014-05-07

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 29

Registration Number: NCT00579501

A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy

Phase 2

Completed

Conditions: Photosensitive Epilepsy

Interventions: Drug: JNJ-26489112
Drug: Placebo

First Posted Date: 2007-12-24

Last Posted Date: 2012-04-05

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 12

Registration Number: NCT00579384

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

Phase 4

Completed

Conditions: Autistic Disorder
Autism

Interventions: Drug: Risperidone low dose
Drug: Risperidone high dose
Drug: Placebo

First Posted Date: 2007-12-19

Last Posted Date: 2014-05-09

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 96

Registration Number: NCT00576732

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

Phase 2

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Placebo
Drug: JNJ-31001074

First Posted Date: 2007-12-03

Last Posted Date: 2014-05-13

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 32

Registration Number: NCT00566449

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Escitalopram
Drug: JNJ-18038683

First Posted Date: 2007-12-03

Last Posted Date: 2014-08-06

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 67

Registration Number: NCT00566202

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Oral Risperidone
Drug: Paliperidone ER

First Posted Date: 2007-09-26

Last Posted Date: 2014-05-09

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 201

Registration Number: NCT00535132

Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: JNJ-18054478
Drug: sham comparator

First Posted Date: 2007-09-17

Last Posted Date: 2014-06-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 26

Registration Number: NCT00530166

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Paliperidone ER

First Posted Date: 2007-09-03

Last Posted Date: 2014-06-04

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 201

Registration Number: NCT00524043

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Paliperidone ER
Drug: Placebo

First Posted Date: 2007-08-20

Last Posted Date: 2014-04-16

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 201

Registration Number: NCT00518323

A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia

Phase 2

Completed

Conditions: Pneumonia, Bacterial
Abdominal Abscess
Pneumonia, Ventilator-Associated
Pneumonia
Bacterial Infections

Interventions: Drug: Imipenem/cilastatin
Drug: Doripenem

First Posted Date: 2007-08-13

Last Posted Date: 2019-03-19

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 146

Registration Number: NCT00515034

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy